IDEAS home Printed from https://ideas.repec.org/r/eee/respol/v36y2007i4p566-589.html
   My bibliography  Save this item

The myth of the biotech revolution: An assessment of technological, clinical and organisational change

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Andreas Reinstaller & Gerhard Schwarz, 2012. "Die wirtschafts- und forschungspolitische Bedeutung der Umsetzung der Biopatentrichtlinie im österreichischen Patentgesetz," WIFO Studies, WIFO, number 44635, June.
  2. Francesco Fallucchi & Jan Niederreiter & Massimo Riccaboni, 2021. "Learning and dropout in contests: an experimental approach," Theory and Decision, Springer, vol. 90(2), pages 245-278, March.
  3. Ali, Ayfer & Gittelman, Michelle, 2016. "Research paradigms and useful inventions in medicine: Patents and licensing by teams of clinical and basic scientists in Academic Medical Centers," Research Policy, Elsevier, vol. 45(8), pages 1499-1511.
  4. Irina Dezhina & V. Kiseleva, 2008. "State, Science and Business in Russia's Innovation System," Research Paper Series, Gaidar Institute for Economic Policy, issue 115P.
  5. Giovanni Dosi & Xiaodan Yu, 2018. "Capabilities Accumulation and Development: What History Tells the Theory," LEM Papers Series 2018/27, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
  6. Vargas-Peláez, Claudia Marcela & Soares, Luciano & Rover, Marina Raijche Mattozo & Blatt, Carine Raquel & Mantel-Teeuwisse, Aukje & Rossi Buenaventura, Francisco Augusto & Restrepo, Luis Guillermo & L, 2017. "Towards a theoretical model on medicines as a health need," Social Science & Medicine, Elsevier, vol. 178(C), pages 167-174.
  7. Roberta Piergiovanni & Enrico Santarelli, 2013. "The more you spend, the more you get? The effects of R&D and capital expenditures on the patenting activities of biotechnology firms," Scientometrics, Springer;Akadémiai Kiadó, vol. 94(2), pages 497-521, February.
  8. Kenneth Zahringer & Christos Kolympiris & Nicholas Kalaitzandonakes, 2018. "Time to patent at the USPTO: the case of emerging entrepreneurial firms," The Journal of Technology Transfer, Springer, vol. 43(4), pages 923-952, August.
  9. DiVito, Lori, 2012. "Institutional entrepreneurship in constructing alternative paths: A comparison of biotech hybrids," Research Policy, Elsevier, vol. 41(5), pages 884-896.
  10. Medina-Molotla, Nelly & Thorsteinsdóttir, Halla & Frixione, Eugenio & Kuri-Harcuch, Walid, 2017. "Some factors limiting transfer of biotechnology research for health care at Cinvestav: A Mexican scientific center," Technology in Society, Elsevier, vol. 48(C), pages 1-10.
  11. Andreas Reinstaller & Gerhard Schwarz, 2013. "Die Bedeutung und Nutzung von Biotechnologie-Patenten in Österreich," WIFO Monatsberichte (monthly reports), WIFO, vol. 86(3), pages 237-251, March.
  12. Nikulainen, Tuomo & Kulvik, Martti, 2009. "How General Are General Purpose Technologies? Evidence from nano-, bio- and ICT-technologies in Finland," Discussion Papers 1208, The Research Institute of the Finnish Economy.
  13. Gilding, Michael & Brennecke, Julia & Bunton, Vikki & Lusher, Dean & Molloy, Peter L. & Codoreanu, Alex, 2020. "Network failure: Biotechnology firms, clusters and collaborations far from the world superclusters," Research Policy, Elsevier, vol. 49(2).
  14. Anckaert, Paul-Emmanuel & Cassiman, David & Cassiman, Bruno, 2020. "Fostering practice-oriented and use-inspired science in biomedical research," Research Policy, Elsevier, vol. 49(2).
  15. repec:grm:ecoyun:201712 is not listed on IDEAS
  16. Billette de Villemeur, Etienne & Scannell, Jack & Versaevel, Bruno, 2021. "Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?," MPRA Paper 108233, University Library of Munich, Germany.
  17. Alberto Onetti & Hal Steger, 2007. "Formulating an open source business model requires community segmentation and targeted marketing," Economics and Quantitative Methods qf0707, Department of Economics, University of Insubria.
  18. Jing Zhang & Charles Baden‐Fuller, 2010. "The Influence of Technological Knowledge Base and Organizational Structure on Technology Collaboration," Journal of Management Studies, Wiley Blackwell, vol. 47(4), pages 679-704, June.
  19. Jorge Niosi & Maureen McKelvey, 2018. "Relating business model innovations and innovation cascades: the case of biotechnology," Journal of Evolutionary Economics, Springer, vol. 28(5), pages 1081-1109, December.
  20. Bergek, Anna & Berggren, Christian & Magnusson, Thomas & Hobday, Michael, 2013. "Technological discontinuities and the challenge for incumbent firms: Destruction, disruption or creative accumulation?," Research Policy, Elsevier, vol. 42(6), pages 1210-1224.
  21. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
  22. Wydra, Sven, 2009. "Production and employment impacts of new technologies: analysis for biotechnology," FZID Discussion Papers 08-2009, University of Hohenheim, Center for Research on Innovation and Services (FZID).
  23. Jing Liu & Mengbo Wang & Xiaoling Kang & Xia Zhang & Xing Chen, 2022. "Seizing the opportunity window of artificial intelligence in China: Towards an innovation policy mix framework for emerging technologies from an evolution perspective," Systems Research and Behavioral Science, Wiley Blackwell, vol. 39(3), pages 397-414, May.
  24. Andersson, Tord & Gleadle, Pauline & Haslam, Colin & Tsitsianis, Nick, 2010. "Bio-pharma: A financialized business model," CRITICAL PERSPECTIVES ON ACCOUNTING, Elsevier, vol. 21(7), pages 631-641.
  25. Alessia Pisoni & Alberto Onetti & Luciano Fratocchi & Marco Talaia, 2010. "Managing R&D activities in the Italian red biotech industry. A comparison between Italian independent firms and multinational companies," Economics and Quantitative Methods qf1003, Department of Economics, University of Insubria.
  26. Varshney, Mayank & Jain, Amit, 2023. "Technology acquisition following inventor exit in the biopharmaceutical industry," Technovation, Elsevier, vol. 126(C).
  27. Dosi, Giovanni & Nelson, Richard R., 2010. "Technical Change and Industrial Dynamics as Evolutionary Processes," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 51-127, Elsevier.
  28. Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
  29. Stuart Hogarth & Paul Martin, 2021. "The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine," Regulation & Governance, John Wiley & Sons, vol. 15(3), pages 969-986, July.
  30. Joanna Chataway & Sarah Parks & Elta Smith, 2017. "How Will Open Science Impact on University-Industry Collaboration?," Foresight and STI Governance (Foresight-Russia till No. 3/2015), National Research University Higher School of Economics, vol. 11(2), pages 44-53.
  31. K D S Fernald & H P G Pennings & J F van den Bosch & H R Commandeur & E Claassen, 2017. "The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-22, February.
  32. Tylecote, Andrew, 2019. "Biotechnology as a new techno-economic paradigm that will help drive the world economy and mitigate climate change," Research Policy, Elsevier, vol. 48(4), pages 858-868.
  33. Antonio Messeni Petruzzelli & Daniele Rotolo & Vito Albino, 2014. "Determinants of Patent Citations in Biotechnology: An Analysis of Patent Influence Across the Industrial and Organizational Boundaries," SPRU Working Paper Series 2014-05, SPRU - Science Policy Research Unit, University of Sussex Business School.
  34. Gittelman, Michelle, 2016. "The revolution re-visited: Clinical and genetics research paradigms and the productivity paradox in drug discovery," Research Policy, Elsevier, vol. 45(8), pages 1570-1585.
  35. Ohid Yaqub, 2018. "Variation in the dynamics and performance of industrial innovation: what can we learn from vaccines and HIV vaccines?," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 27(1), pages 173-187.
  36. Nahuis, Roel & Stemerding, Dirk, 2013. "Genomics as a new research regime? Evidence from the Netherlands," Research Policy, Elsevier, vol. 42(3), pages 676-687.
  37. Chen, Shih-Hsin & Lin, Wei-Ting, 2017. "The dynamic role of universities in developing an emerging sector: a case study of the biotechnology sector," Technological Forecasting and Social Change, Elsevier, vol. 123(C), pages 283-297.
  38. Lauto, Giancarlo & Valentin, Finn, 2016. "The knowledge production model of the New Sciences: The case of Translational Medicine," Technological Forecasting and Social Change, Elsevier, vol. 111(C), pages 12-21.
  39. Fabio Sorrentino & Francesco Garraffo, 2012. "Explaining performing R&D through alliances: Implications for the business model of Italian dedicated biotech firms," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 16(3), pages 449-475, August.
  40. Clemens Blümel, 2018. "Translational research in the science policy debate: a comparative analysis of documents," Science and Public Policy, Oxford University Press, vol. 45(1), pages 24-35.
  41. Valérie Sabatier & Vincent Mangematin & Tristan Rouselle, 2010. "From Business model to Business model portfolio in the european biopharmaceutical industry," Post-Print hal-00430782, HAL.
  42. Ribeiro, Barbara & Shapira, Philip, 2020. "Private and public values of innovation: A patent analysis of synthetic biology," Research Policy, Elsevier, vol. 49(1).
  43. Kotiranta, Annu – Kulvik & Tahvanainen, Antti – Trieste, . "Raiders Of Lost Value," ETLA B, The Research Institute of the Finnish Economy, number 267.
  44. Aarden, Erik & Van Hoyweghen, Ine & Horstman, Klasien, 2011. "Constructing access in predictive medicine. Comparing classification for hereditary breast cancer risks in England, Germany and the Netherlands," Social Science & Medicine, Elsevier, vol. 72(4), pages 553-559, February.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.